课题基金 / 基金详情

Establishment of treatment of Duchenne muscular dystrophy

Establishment of treatment of Duchenne muscular dystrophy
杜氏肌营养不良症治疗方法的建立
批准号:
12557068
负责人:
MATSUO Masafumi
金额:
$8.58万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
2000
资助国家:
日本
项目状态:
已结题
起止时间:
2000 至 2001

项目摘要

项目成果

MATSUO Masafumi的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
It has been proposed that Duchenne muscular dystrophy can be treated with modification of out-of-frame mutation into in-frame mutation by inducing exon skipping. In this study the possibility to treat DMD was evaluated by seeing inducibility of exon skipping. In the previous study we showed exon 19 skipping can be induced by blocking the function of splicing enhancer sequence with antisense oligonucleotides. To apply this strategy we looked for splicing enhancer sequence in exons that are located in deletion hot spots. From exon sequence purine-rich sequence were extracted as candidate sequences for splicing enhancer sequence and splicing enhancer activity of those candidate sequences were analyzed by using Drosophilla dsx minigene. Thereby some antisense oligonucleotides were found to have an ability to induce exon skipping.
期刊论文(36)
专著(0)
科研奖励(0)
会议论文
Ito, T, Takeshima, Y, Nakamura, H, Matsuo, M.: "One of three examined purine-rich sequences selected from dystrophin exons exhibits splicing enhancer activity"Acta Myologica. 20. 151-153 (2001)
Ito, T, Takeshima, Y, Nakamura, H, Matsuo, M.:“从抗肌营养不良蛋白外显子中选出的三个经过检查的富含嘌呤的序列之一表现出剪接增强子活性”Acta Myologica。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Ito T.: "One of three examined purine-rich sequence selected from dystrophin exons exhibits splicing enhancer activity"Acta Myologica. 2. 151-153 (2001)
Ito T.:“从肌营养不良蛋白外显子中选择的三个经检查的富含嘌呤的序列之一表现出剪接增强子活性”Acta Myologica。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Matsuo M.: "Treatment of Duchenne muscular dystrophy at the mRNA level"Frontiers in human genetics diseases and technologies. 347-361 (2001)
Matsuo M.:“在 mRNA 水平上治疗杜氏肌营养不良症”人类遗传疾病和技术的前沿。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Takeshima Y.: "Nakamura, H, Matsuo, M. Oligonucleotides against a splicing enhancer sequence led to dystrophin production in muscle cells from a Duchenne muscular dystrophy patient."Brain Dev.. 23. 788-798 (2001)
Takeshima Y.:“Nakamura, H, Matsuo, M.针对剪接增强子序列的寡核苷酸导致杜氏肌营养不良症患者的肌肉细胞中产生肌营养不良蛋白。”Brain Dev.. 23. 788-798 (2001)
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
15
    Cloning of non-dystrophin transcript from the dystrophin gene
    • 批准号:
      25670480
    • 项目类别:
      Grant-in-Aid for Challenging Exploratory Research
    • 资助金额:
      $2.5万
    • 财政年份:
      2013
    • 负责人:
      MATSUO Masafumi
    • 依托单位:
    Expression of dystrophin via exon skipping with a small chemical
    • 批准号:
      24390267
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $11.65万
    • 财政年份:
      2012
    • 负责人:
      MATSUO Masafumi
    • 依托单位:
    Dose prostaglandin-mediated inflammation commit to pathology of Duchenne muscular dystrophy?
    • 批准号:
      23659521
    • 项目类别:
      Grant-in-Aid for Challenging Exploratory Research
    • 资助金额:
      $2.5万
    • 财政年份:
      2011
    • 负责人:
      MATSUO Masafumi
    • 依托单位:
    Genes responsible for mental retardation complicating to Duchenne muscular dystrophy
    国内基金
    海外基金
    CircSLTM及其编码多肽SLTM-99aa通过SAFB介导的mRNA剪接重塑在胃癌发生发展中的分子机制及其临床价值研究
    • 批准号:
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2025
    • 负责人:
      胡柯峰
    • 依托单位:
    5'-tRF-GlyGCC通过SRSF1调控RNA可变剪切促三阴性乳腺癌作用机制及干预策略
    • 批准号:
      82372743
    • 项目类别:
      面上项目
    • 资助金额:
      49.00万元
    • 批准年份:
      2023
    • 负责人:
      陈卓佳
    • 依托单位:
    MEK/ERK通路对Bim选择性剪接的调节及其在胃癌细胞对化疗敏感性中作用
    • 批准号:
      81071809
    • 项目类别:
      面上项目
    • 资助金额:
      33.0万元
    • 批准年份:
      2010
    • 负责人:
      张旭东
    • 依托单位:
    c-Abl调控U2AF65介导的mRNA剪接及核质转运机制研究